Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorFudan University
About this trial
The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
Eligibility criteria
Qualifiers
Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
Age 18-80 years at time of signing informed consent (including threshold);
ECOG score 0 or 1;
No previous surgery for lung cancer;
Disqualifiers
T1N0M0 with a clinical stage other than 0.5 < CTR < 1 and a diameter of ≤ 2 cm;
Inability to perform complete surgical resection;
cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
Previous surgery for lung cancer;
Trial design
Treatments tested in this trial
- Selective lymph node dissection
Treatment groups
684 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov